Bioactivity-Guided Identification and Cell Signaling Technology to Delineate the Lactate Dehydrogenase A Inhibition Effects of Spatholobus suberectus on Breast Cancer

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Wang, Zhiyu ^a   Wang, Dongmei ^b   Han, Shouwei ^c   Wang, Neng ^a   Mo, Feizhi ^a   Loo, Tjing Yung ^a   Shen, Jiangang ^a   Huang, Hui ^b   Chen, Jianping ^a  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SUN YAT SEN UNIVERSITY   (China)

^c GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CATECHIN; EPICATECHIN; EPIGALLOCATECHIN; ESTROGEN; GALLOCATECHIN; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE ISOENZYME 5; PLANT EXTRACT; REACTIVE OXYGEN METABOLITE; SPATHOLOBUS SUBERECTUS EXTRACT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOACTIVITY GUIDED FRACTIONATION; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; FRACTIONATION; HERB; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SPATHOLOBUS SUBERECTUS; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CATECHIN; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FABACEAE; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISOENZYMES; L-LACTATE DEHYDROGENASE; M PHASE CELL CYCLE CHECKPOINTS; MICE; PLANT EXTRACTS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874002588     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056631     Document Type: Article

References (39)

1. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
2. Vander Heiden MG, (2011) Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10: 671-684.
3. Cairns RA, Harris IS, Mak TW, (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11: 85-95.
4. Warburg O, (1956) On the origin of cancer cells. Science 123: 309-314.
5. Pelicano H, Martin DS, Xu RH, Huang P, (2006) Glycolysis inhibition for anticancer treatment. Oncogene 25: 4633-4646.
6. Gatenby RA, Gillies RJ, (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899.
7. Hirschhaeuser F, Sattler UG, Mueller-Klieser W, (2011) Lactate: a metabolic key player in cancer. Cancer Res 71: 6921-6925.
8. Lu H, Forbes RA, Verma A, (2002) Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 277: 23111-23115.
9. Gordan JD, Thompson CB, Simon MC, (2007) HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 12: 108-113.
10. Gatenby RA, Gillies RJ, (2007) Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol 39: 1358-1366.
11. Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, et al. (2010) Evidence for an alternative glycolytic pathway in rapidly proliferating cells. 2010; 329: 1492-1499.
12. Shi HS, Li D, Zhang J, Wang YS, Yang L, et al. (2010) Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice. Cancer Sci 101: 1447-1453.
13. Kolev Y, Uetake H, Takagi Y, Sugihara K, (2008) Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia- inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis. Ann Surg Oncol 15: 2336-2344.
14. Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, et al. (2009) LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther 8: 626-635.
15. Wang ZY, Loo TY, Shen JG, Wang N, Wang DM, et al. (2012) LDH-A silencing suppresses breast cancer tumorigenicity through induction of oxidative stress mediated mitochondrial pathway apoptosis. Breast Cancer Res Treat 131: 791-800.
16. Fantin VR, St-Pierre J, Leder P, (2006) Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9: 425-434.
17. Takahashi Y, Miyajima H, Kaneko E, (1995) Genetic analysis of a family of lactate dehydrogenase A subunit deficiency. Intern Med 34: 326-329.
18. Granchi C, Bertini S, Macchia M, Minutolo F, (2010) Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Curr Med Chem 17: 672-697.
19. Wang Z, Wang N, Chen J, Shen J, (2012) Emerging glycolysis targeting and drug discovery from Chinese medicine in cancer therapy. Evid Based Complement Alternat Med 2012: 873175.
20. Yang DM, (2003) Applaction of Spatholobus suberectus in treating leucopenia caused by radiotherapy. Journal of Traditional Chinese Medicine 44: 730.
21. Chen DH, Luo X, Yu MY, Zhao YQ, Cheng YF, et al. (2004) Effect of Spatholobus suberectus on the bone marrow cells and related cytokines of mice. Zhongguo Zhong Yao Za Zhi 29: 352-355.
22. Wang ZY, Wang DM, Loo TY, Cheng Y, Chen LL, et al. (2011) Spatholobus suberectus inhibits cancer cell growth by inducing apoptosis and arresting cell cycle at G2/M checkpoint. J Ethnopharmacol 133: 751-758.
23. Cheng XL, Wan JY, Li P, Qi LW, (2011) Ultrasonic/microwave assisted extraction and diagnostic ion filtering strategy by liquid chromatography-quadrupole time-of-flight mass spectrometry for rapid characterization of flavonoids in Spatholobus suberectus. J Chromatogr A 1218: 5774-5786.
24. Yoon JS, Sung SH, Park JH, Kim YC, (2004) Flavonoids from Spatholobus suberectus. Arch Pharm Res 27: 589-592.
25. Clark AS, West K, Streicher S, Dennis PA, (2002) Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1: 707-717.
26. Minet E, Mottet D, Michel G, Roland I, Raes M, et al. (1999) Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett 460: 251-256.
27. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, et al. (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277: 29936-29944.
28. Brentani MM, Nagai MA, (1983) Lactate dehydrogenase in breast carcinoma: correlation with estrogen and progesterone receptors. Cancer Detect Prev 6: 241-247.
29. Burke RE, Harris SC, McGuire WL, (1978) Lactate dehydrogenase in estrogen- responsive human breast cancer cells. Cancer Res 38: 2773-2776.
30. Ocana A, Pandiella A, Siu LL, Tannock IF, (2010) Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol 8: 200-209.
31. Guo W, Kong E, Meydani M, (2009) Dietary polyphenols, inflammation, and cancer. Nutr Cancer 61: 807-810.
32. Gu L, Kelm MA, Hammerstone JF, Beecher G, Holden J, et al. (2003) Screening of foods containing proanthocyanidins and their structural characterization using LC-MS/MS and thiolytic degradation. J Agric Food Chem 51: 7513-7521.
33. Kuzuhara T, Suganuma M, Fujiki H, (2008) Green tea catechin as a chemical chaperone in cancer prevention. Cancer Lett 261: 12-20.
34. Yang CS, Wang X, Lu G, Picinich SC, (2009) Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 9: 429-439.
35. Vergote D, Cren-Olivé C, Chopin V, Toillon RA, Rolando C, et al. (2002) (-)-Epigallocatechin (EGC) of green tea induces apoptosis of human breast cancer cells but not of their normal counterparts. Breast Cancer Res Treat 76: 195-201.
36. Kushima Y, Iida K, Nagaoka Y, Kawaratani Y, Shirahama T, et al. (2009) Inhibitory effect of (-)-epigallocatechin and (-)-epigallocatechin gallate against heregulin beta1-induced migration/invasion of the MCF-7 breast carcinoma cell line. Biol Pharm Bull 32: 899-904.
37. Liu YV, Semenza GL, (2007) RACK1 vs. HSP90: competition for HIF-1 alpha degradation vs. stabilization. Cell Cycle 6: 656-659.
38. Minet E, Mottet D, Michel G, Roland I, Raes M, et al. (1999) Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett 460: 251-256.
39. Semenza GL, (2010) HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20: 51-56.